Veracyte Inc (VCYT)

$30.76 0.67 (2.23%)

16:13 EDT VCYT Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 1.06B

PE Ratio -32.72

EPS -0.94

Volume (Avg. Vol.) 489,000

Day's Range 29.72 - 30.90

52-Week Range 13.90 - 36.42

Dividend & Yield N/A (N/A)

VCYT Stock Predictions, Articles, and Veracyte Inc News

From the Web

Technical Analysis Of US Stocks: VCYT, VRSK, WDAY, WKHS, WORK, XLNX, Z, ZS

From Talk Markets Sep 25, 2020

A technical analysis covering Veracyte Inc, Verisk Analytics, Workday Inc, Workhorse Inc, Slack tech Inc, Xilinx Inc, Zillow and Zscaler.

Veracyte lung disease test nabs special status to allow market-based U.S. pricing (NASDAQ:VCYT)

From Seeking Alpha Sep 24, 2020

Veracyte (NASDAQ:VCYT) announced that the Centers for Medicare and Medicaid Services has approved new Advanced Diagnostic Laboratory Test status for the Envisia® Genomic Classifier.Veracyte’s Envisia classifier is the first and only genomic test that helps improve diagnosis of idiopathic pulmonary fibrosis and other interstitial lung diseases.During the nine-month period prior to the new pricing, the Envisia classifier will be reimbursed at a rate of $5,500 for all Medicare patients.“Importantly, we believe this milestone also helps position the Envisia classifier for reimbursement expansion as we move into 2021 and beyond.” said Bonnie Anderson, Chairman and CEO.

Veracyte's Envisia Genomic Classifier receives ADLT status from CMS (NASDAQ:VCYT)

From Seeking Alpha Sep 24, 2020

Veracyte (NASDAQ:VCYT) announced that the Centers for Medicare and Medicaid Services has approved new Advanced Diagnostic Laboratory Test status for the Envisia® Genomic Classifier.Veracyte’s Envisia classifier is the first and only genomic test that helps improve diagnosis of idiopathic pulmonary fibrosis and other interstitial lung diseases.During the nine-month period prior to the new pricing, the Envisia classifier will be reimbursed at a rate of $5,500 for all Medicare patients.“Importantly, we believe this milestone also helps position the Envisia classifier for reimbursement expansion as we move into 2021 and beyond.” said Bonnie Anderson, Chairman and CEO.

Technical Short Put Spread Fade the Dip Trade and Trigger in Veracyte Inc

From Capital Market Laboratories Aug 12, 2020

The Techncial Trigger Driven Option Trade Right Before Veracyte Inc (NASDAQ:VCYT) Earnings.

Benzinga's Top Upgrades, Downgrades For September 9, 2020

From Benzinga Sep 9, 2020

Upgrades For Duke Energy Corp (NYSE: DUK), B of A Securities upgraded the previous rating of Neutral to the current rating Buy. In the second quarter, Duke Energy showed an EPS...

Veracyte prices equity offering at $30 (NASDAQ:VCYT)

From Seeking Alpha Aug 5, 2020

Veracyte (NASDAQ:VCYT) has priced its public offering of 6M common shares at $30.00/share, for expected gross proceeds of $180M.

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy